Industry Strength Score
66/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
AYTU BIOPHARMA INC (AYTU) Stock Price & Overview
NASDAQ:AYTU • US0547548588
Current stock price
2.61 USD
+0.03 (+1.16%)
Last:
The current stock price of AYTU is 2.61 USD. Today AYTU is up by 1.16%. In the past month the price decreased by -2.27%. In the past year, price increased by 96.96%.
AYTU Key Statistics
52-Week Range1.2 - 3.065
Current AYTU stock price positioned within its 52-week range.
1-Month Range2.454 - 2.735
Current AYTU stock price positioned within its 1-month range.
- Market Cap
- 28.005M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.55
- Dividend Yield
- N/A
AYTU Stock Performance
Today
+1.16%
1 Week
+2.38%
1 Month
-2.27%
3 Months
-0.77%
Longer-term
6 Months +13.66%
1 Year +96.96%
2 Years -8.19%
3 Years +9.79%
5 Years -98.05%
10 Years N/A
AYTU Stock Chart
AYTU Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to AYTU. When comparing the yearly performance of all stocks, AYTU is one of the better performing stocks in the market, outperforming 89.51% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
AYTU Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AYTU. AYTU may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
AYTU Earnings
On February 3, 2026 AYTU reported an EPS of -1.05 and a revenue of 15.16M. The company missed EPS expectations (-71.57% surprise) and beat revenue expectations (22.12% surprise).
Next Earnings DateMay 18, 2026
Last Earnings DateFeb 3, 2026
PeriodQ2 / 2026
EPS Reported-$1.05
Revenue Reported15.165M
EPS Surprise -71.57%
Revenue Surprise 22.12%
AYTU Forecast & Estimates
9 analysts have analysed AYTU and the average price target is 9.86 USD. This implies a price increase of 277.78% is expected in the next year compared to the current price of 2.61.
For the next year, analysts expect an EPS growth of 33.48% and a revenue growth -18.12% for AYTU
Analysts
Analysts82.22
Price Target9.86 (277.78%)
EPS Next Y33.48%
Revenue Next Year-18.12%
AYTU Financial Highlights
Over the last trailing twelve months AYTU reported a non-GAAP Earnings per Share(EPS) of -3.55. The EPS decreased by -206.03% compared to the year before.
Income Statements
Revenue(TTM)62.64M
Net Income(TTM)-24.44M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.04% | ||
| ROE | -172.12% | ||
| Debt/Equity | 1.34 |
Chartmill High Growth Momentum
EPS Q2Q%-303.85%
Sales Q2Q%-6.51%
EPS 1Y (TTM)-206.03%
Revenue 1Y (TTM)-8.91%
AYTU Ownership
Ownership
Inst Owners35.17%
Shares10.73M
Float9.77M
Ins Owners8.41%
Short Float %5.14%
Short Ratio12.14
AYTU Industry Overview
AYTU operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
34%
Outperformed 34% of sub-industries
3 Month Rank
52%
Outperformed 52% of sub-industries
6 Month Rank
39%
Outperformed 39% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 4.4%
- New Lows
- 3.7%
- Average ROE
- 51.3%
- Average Profit Margin
- 27.9%
- Average Operating Margin
- 37.7%
- Average P/E
- 25.7
- Average Fwd P/E
- 17.9
- Average Debt/Equity
- 1.2
AYTU Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 22.66 | 883.029B | ||
| JNJ | JOHNSON & JOHNSON | 17.98 | 553.619B | ||
| MRK | MERCK & CO. INC. | 11.48 | 269.662B | ||
| PFE | PFIZER INC | 8.85 | 151.879B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.52 | 123.709B | ||
| ZTS | ZOETIS INC | 16.14 | 48.347B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.54 | 28.899B | ||
| VTRS | VIATRIS INC | 6.01 | 17.396B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.4 | 11.171B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 10.626B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.109B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.971B | ||
| CORT | CORCEPT THERAPEUTICS INC | 34.75 | 4.948B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AYTU
Company Profile
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. The company is headquartered in Denver, Colorado and currently employs 82 full-time employees. The company went IPO on 2017-10-20. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.
Company Info
IPO: 2017-10-20
AYTU BIOPHARMA INC
7900 E. Union Avenue, Suite 920
Denver COLORADO 80112 US
CEO: Joshua R. Disbrow
Employees: 83
Phone: 13026365400
AYTU BIOPHARMA INC / AYTU FAQ
Can you describe the business of AYTU BIOPHARMA INC?
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. The company is headquartered in Denver, Colorado and currently employs 82 full-time employees. The company went IPO on 2017-10-20. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.
Can you provide the latest stock price for AYTU BIOPHARMA INC?
The current stock price of AYTU is 2.61 USD. The price increased by 1.16% in the last trading session.
Does AYTU stock pay dividends?
AYTU does not pay a dividend.
How is the ChartMill rating for AYTU BIOPHARMA INC?
AYTU has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does AYTU BIOPHARMA INC belong to?
AYTU BIOPHARMA INC (AYTU) operates in the Health Care sector and the Pharmaceuticals industry.
What is the employee count for AYTU stock?
AYTU BIOPHARMA INC (AYTU) currently has 83 employees.